BIO-key International, Inc. (BKYI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights improved financial metrics, including increased gross margins and cash position, despite a slight increase in net loss. The Q&A reveals optimistic guidance with potential growth in strategic sectors and regions, supported by partnerships. The announcement of PortalGuard Version 7 and a significant contract renewal further bolster the outlook. While some uncertainties remain, such as the reverse stock split, the overall sentiment leans positive due to strong future prospects and strategic initiatives.
Key Financial Performance
2025 Total Revenue $6.1 million, a 12% decrease year-over-year from $6.9 million in 2024. The decline was attributed to a $1.5 million 2-year license renewal with a foreign national bank recorded mostly in 2024, and the strategic transition to selling only BIO-key-branded solutions in the EMEA region.
Hardware Revenue $1.3 million in 2025, over 100% increase year-over-year. This growth was driven by increased purchases of Biometric Solutions.
Service Revenue $1.2 million in 2025, a 6% increase year-over-year. The increase was due to BIO-key's growing customer base and new customer deployments.
Gross Margin 77.5% in 2025, down from 81.4% in 2024. The decline was primarily due to the mix of software license fee revenue and hardware revenue as a percentage of total revenues. However, gross margins on license fees improved to 91% in 2025 from 88% in 2024 due to selling branded products in the EMEA region.
SG&A Costs Reduced by 11% in 2025, amounting to a decrease of approximately $800,000. This reduction was achieved through proactive cost management, including reorganization of sales personnel, reduced marketing show expenses, and lower audit fees.
Operating Expenses Decreased by 7% in 2025. This was due to lower SG&A costs, partially offset by a 4% increase in research and development engineering costs to support new product development.
Net Loss $4.6 million in 2025, an increase from $4.3 million in 2024. The increase was due to lower revenue despite reduced operating costs.
Cash Position $2.7 million at the end of 2025, up from $438,000 at the end of 2024. This increase was attributed to improved financial management and activities.
Book Value $7.6 million at the end of 2025, up from $3.8 million at the end of 2024. This reflects an improvement in the company's financial position.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New FBI FAP 20 Certified EcoID III fingerprint scanner: BIO-key introduced the EcoID III fingerprint scanner, which features encrypted device-to-host communication and liveness detection for secure authentication. It is targeted at highly regulated industries like defense and banking.
PortalGuard Identity platform Version 7.0: BIO-key is finalizing its most significant update to the PortalGuard Identity platform, Version 7.0, which includes platform monetization, configurability, flexibility, and lower-cost deployment capabilities. It is expected to release in Q2 2026.
Defense & Intelligence Cybersecurity Initiative: BIO-key launched this initiative in 2025, focusing on defense and financial sectors, with significant new partnerships domestically and internationally.
Global authentication solutions market growth: The market is projected to grow from $23 billion in 2025 to nearly $100 billion by 2035, driven by the need for secure access to digital platforms and protection against cybersecurity threats.
Cost reduction in SG&A expenses: BIO-key reduced SG&A expenses by 11% in 2025 through reorganization of sales personnel, reduced marketing expenses, and lower audit fees.
Improved financial position: BIO-key ended 2025 with $2.7 million in cash, up from $438,000 in 2024, and increased its book value to $7.6 million from $3.8 million in 2024.
Transition to BIO-key-branded solutions in EMEA: BIO-key completed its transition to selling only BIO-key-branded solutions in the EMEA region, improving gross margins and growth prospects.
Focus on passwordless and biometric authentication: BIO-key is emphasizing passwordless, tokenless, and phoneless authentication solutions, leveraging biometrics to address vulnerabilities in traditional methods.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Performance: 2025 revenue decreased by 12% to $6.1 million compared to $6.9 million in 2024, primarily due to timing issues with a $1.5 million 2-year license renewal and the transition to selling only BIO-key-branded solutions in the EMEA region.
Gross Margin Decline: Gross margin decreased to 77.5% in 2025 from 81.4% in 2024, driven by a higher mix of hardware revenue, which has lower margins compared to software license fees.
Net Loss Increase: Net loss increased to $4.6 million in 2025 from $4.3 million in 2024, reflecting lower revenue and increased R&D costs.
Regulatory and Compliance Risks: The company operates in highly regulated industries such as defense and banking, which require strict compliance with evolving regulations, posing potential challenges.
Geopolitical Risks: Escalating geopolitical risks and AI-driven threats could impact the adoption and deployment of authentication solutions.
Operational Efficiency: While SG&A costs were reduced by 11% in 2025, further cost management is critical to achieving breakeven and profitability in 2026.
Product Development Costs: R&D costs increased by 4% in 2025 to support new product development, which could strain financial resources if not offset by revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: BIO-key anticipates Q1 2026 revenue of approximately $2.2 million, representing a 37% increase over Q1 2025 and a sequential improvement over Q4 2025. The company expects top-line expansion in 2026.
Profitability Goals: The company aims to achieve breakeven and profitability in 2026, supported by top-line growth and expense management.
Market Trends: The global authentication solutions market is projected to grow from $23 billion in 2025 to nearly $100 billion by 2035, with a compound annual growth rate of almost 16%. Increasing adoption of passwordless authentication and biometric solutions is expected, particularly in regulated industries such as military, defense, financial services, and healthcare.
Product Development: BIO-key plans to release PortalGuard Identity platform Version 7.0 in Q2 2026, featuring significant updates, configurability, and lower-cost deployment capabilities. The company also introduced the FBI FAP 20 Certified EcoID III fingerprint scanner for highly regulated industries.
Strategic Focus: The company is focusing on passwordless, tokenless, and phoneless authentication solutions, which are expected to become the default for workforce access by the end of 2026. BIO-key's solutions aim to address vulnerabilities in traditional authentication methods and meet evolving regulatory requirements.
Financial Position: BIO-key ended 2025 with $2.7 million in cash and a book value of $7.6 million, providing a solid working capital base to support growth plans for 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why was the 2025 revenue softer than initially expected?
A:The 2025 revenue was softer due to a significant contract renewal with a foreign retail bank in 2024 that did not benefit 2025. The contract was a 2-year deal closed in 2024, with revenue recognized entirely in that year. Additionally, a transition in the EMEA division took longer than expected, impacting 2025 performance. However, this transition is expected to yield benefits in 2026 and beyond.
Q:Is the foreign retail bank mentioned in the press release the same customer from 2024?
A:Yes, the foreign retail bank mentioned in the press release is the same customer from 2024.
Q:What is the revenue mix for the first quarter of 2026, and what are the gross margins?
A:The majority of the revenue for the first quarter of 2026 is expected to come from license revenue, with some strong hardware revenue as well. Gross margins are expected to be in the high 70s to low 80s, with a blended gross margin of 80% or more.
Q:Where are the largest potential deals and opportunities for the company?
A:The largest potential deals and opportunities are in defense, government, financial services, and regulated industries. Geographically, opportunities are spread across EMEA, Europe, the Middle East, and South America. The company is also leveraging its partnership with TD Synnex to expand in the U.S. public sector.
Q:What are the expected expenses for the first quarter and R&D in 2026?
A:Expenses for the first quarter are expected to be stable, with some potential increases due to events or website relaunch costs. R&D expenses in 2026 are expected to remain stable, with a focus on efficiency and cost reduction through AI-related tools.
Q:What is significant about the upcoming PortalGuard platform Version 7?
A:PortalGuard Version 7 includes significant upgrades, such as multi-tenant management for partners, enhanced security features, incorporation of mobile technologies, and the ability to transition seamlessly between on-prem and cloud solutions. These features aim to make the platform more partner-friendly and versatile.
Q:What is the status of the $1 million foreign bank renewal?
A:The $1 million foreign bank renewal saw a 30% increase in value and includes the assessment of advanced technologies like one-to-many, which could significantly expand the contract size in the future.
Q:What is the company's goal for breakeven profitability and cash flow?
A:The company aims to achieve breakeven profitability and be cash flow positive in the early part of 2026.
Q:Is there evidence of U.S. businesses adopting BIO-key solutions over competitors?
A:Yes, there is evidence of U.S. businesses adopting BIO-key solutions, supported by the partnership with TD Synnex, which is expected to drive growth in the public sector.
Q:What is the status of the Boumarang asset?
A:The Boumarang asset remains unchanged in value. The company is aware of an S-1 filing and some acquisitions by Boumarang but has no additional information.
Q:What is the company's plan regarding the potential reverse stock split?
A:The company has filed a proxy for a potential reverse stock split to maintain its NASDAQ listing. If the stock trades above $1 for 10 consecutive days before early May, the reverse split will not be necessary. However, the company is prepared to proceed with the split if required.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on first-quarter expenses and R&D costs, stating only that they are expected to remain stable. Additionally, they did not provide concrete evidence or examples of deals supporting the partnership with TD Synnex, nor did they elaborate on the advanced technologies being assessed by the foreign bank renewal.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Authentication
Ceci
EcoID III
Passkey
adoption
attack
authentication solution
breakeven profitability
comparison
compliance
defense banking
defense service
device
efficiency
enterprise authentication
expansion
flexibility
focus
goal breakeven
improvement
industry
license renewal
military defense
mission
momentum
need
offering
partnership
passwordless authentication
position cash
prospect
relationship
role
shift
system
term
threat
today press
tokenless
trust
workforce
BKYI Transcript
BIO-key International, Inc. (BKYI) Q1 2026 Earnings Call Transcript
Positive5-18
The earnings call reveals strong revenue growth expectations, improved net loss, and positive market trends in authentication solutions. Product developments and strategic focuses align with market needs, and financial health is stable with no funding issues. The Q&A session highlights optimism for future opportunities and a strong pipeline, despite some challenges in U.S. contracts. Overall, the positive elements outweigh the negatives, suggesting a likely positive stock price movement.
BIO-key International, Inc. (BKYI) Q4 2025 Earnings Call Transcript
Positive3-31
The earnings call highlights improved financial metrics, including increased gross margins and cash position, despite a slight increase in net loss. The Q&A reveals optimistic guidance with potential growth in strategic sectors and regions, supported by partnerships. The announcement of PortalGuard Version 7 and a significant contract renewal further bolster the outlook. While some uncertainties remain, such as the reverse stock split, the overall sentiment leans positive due to strong future prospects and strategic initiatives.
BIO-key International, Inc. (BKYI) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call presents a mixed picture. Financial performance shows a slight decline in gross margin and increased net loss, but cash position improved significantly. Product development is positive with new contracts and high-quality offerings. Market strategy is strong with potential expansions and partnerships. However, flat revenues and management's vague responses in the Q&A raise concerns. The strategic plan indicates optimism for future growth, but immediate financial metrics and unclear guidance limit positive sentiment. Overall, the stock reaction is likely neutral in the short term, balancing positive long-term prospects with current challenges.
BIO-key International, Inc. (BKYI) Q2 2025 Earnings Conference Call Transcript
Positive8-13
The earnings call highlights strong revenue growth (49% increase), reduced SG&A expenses, and a significant reduction in note payable. Despite a slight decline in gross margin, the overall financial performance is robust. The Q&A section reveals confidence in future growth, especially in defense and cybersecurity markets. Although management avoided specific guidance, the positive contract activity and expected breakeven achievement provide a positive outlook. The lack of market cap data suggests a neutral to positive reaction, but given the strong financials and growth prospects, a positive sentiment is warranted.
BKYI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
